Clinical Trial

Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

Study acronym: SWITCH-ON
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 5 locations 2026-06-09
Trial Details
NCT Number NCT07313176
Lead Sponsor Britannia Pharmaceuticals Ltd.
Conditions Advanced Parkinson Disease
Enrollment 215 participants
Start Date 2026-05-08
Primary Completion 2028-10 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08